ArticleInternational urology and nephrology2019
More lymph node dissection improves survival in patients with newly diagnosed lymph node-positive penile cancer.
Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- Incarcerated lateral inguinal hernia following ilioinguinal lymph node dissection: an unusual case.Journal of surgical case reports · 2025Article
- Impact of Examined Lymph Node Count and Lymph Node Density on Overall Survival of Penile Cancer.Frontiers in oncology · 2021Article
- Nomogram prediction of overall survival based on log odds of positive lymph nodes for patients with penile squamous cell carcinoma.Cancer medicine · 2020Article
- Advantages of gross total resection in patients with astrocytoma: A population-based study.Oncology letters · 2020Article
- Nomograms to predict overall and cancer-specific survival in patients with penile cancer.Translational cancer research · 2020Article
- Surgical Compliance and Survival Outcomes for Patients with Stage T1-2 Non-Small-Cell Lung Cancer.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeFor patients with lymph node-positive (LN+) penile cancer, the optimal extent of lymph node dissection (LND) is currently not established. We aimed to reveal the potential association between survival and the number of LND in patients with newly diagnosed LN + penile cancer.
methodsPatients with LN + penile cancer diagnosed between 2004 and 2015 were identified using the SEER database. The relationships between the number of removed lymph nodes and overall survival (OS), all-cause mortality (ACM), cancer-specific mortality (CSM), and 5-year mortality were tested. Kaplan-Meier curves as well as univariate and multivariable cox regression were used to further analyze disparities in mortality and survival.
resultsAmong 599 eligible patients with LN + penile cancer, 527 (88.0%) received surgery and 72 (12.0%) did not. Compared with those who had not received surgery, patients receiving surgery had longer overall survival (28.31 ± 30.84 versus 16.69 ± 21.68 months) and longer median survival (15.00 versus 8.00 months) times. Univariate analyses demonstrated the number of LND to be an independent factor. Multivariable Cox regression analyses suggested that the ≥ 8 removed lymph nodes predicted a lower ACM rate (hazard ratio (HR) = 0.48, 95% CI 0.38-0.61, p < 0.001), penile CSM rate (HR = 0.42, 95% CI 0.30-0.57, p < 0.001), and lower 5-year mortality (HR = 0.58, 95% CI 0.47-0.71, p < 0.001).
conclusionsIn patients with newly diagnosed LN + penile cancer, more LND during lymphadenectomy was associated with an improvement in ACM, CSM rate, and 5-year mortality. Therefore, patients with preoperatively LN + penile cancer should undergo LND to have more lymph nodes removed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.